March 22, 2017
Sanofi’s PCSK9 inhibitor Praluent (alirocumab), launched in Japan last September, demonstrated consistent efficacy and safety in diabetic and non-diabetic Japanese patients with hypercholesterolemia, the latest data show. In a PIII study dubbed ODYSSEY JAPAN, 215 patients (ITT population) were stratified...read more